Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLECAPRO
2022-500814-24-00Phase 3Authorised
- Sponsor
- Oslo University Hospital
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of flecainide and metoprolol in mitral valve prolapse (MVP) and ventricular tachyarrhythmia (2 arms), sponsored by Oslo University Hospital. Primary endpoint: Number of ventricular tachyarrhythmias. Planned start Sep 2022; status: authorised.
02
Drugs
flecainidemetoprolol
03
Conditions
mitral valve prolapse (MVP)ventricular tachyarrhythmia
Beyond the preview
Go deeper on 2022-500814-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500814-24-00.